

## Deepak Nitrite Ltd. (DNL)

No. of shares (m)	136.4
Mkt cap (Rs crs/\$m)	31231/4148.6
Current price (Rs/\$)	2290/30.4
Price target (Rs/\$)	2723/36.2
52 W H/L (Rs.)	3020/1077
Book Value (Rs/\$)	225/3.0
Beta	1.2
Daily volume NSE (avg. monthly)	682120
P/BV (FY22e/23e)	9.6/7.1
EV/EBITDA (FY22e/23e)	19.2/16.4
P/E (FY22e/23e)	29.6/25.2
EPS growth (FY21/22e/23e)	26.2/35.6/17.5
OPM (FY21/22e/23e)	28.7/23.7/25.4
ROE (FY21/22e/23e)	40.4/38.3/32.5
ROCE(FY21/22e/23e)	30.2/32.7/30.0
D/E ratio (FY21/22e/23e)	0.3/0.2/0.1
BSE Code	506401
NSE Code	DEEPAKNT
Bloomberg	DN IN
Reuters	DPNT.NS

## Shareholding pattern

	%
Promoters	45.7
MFs / Banks / FIs	10.7
Foreign Portfolio Investors	8.8
Govt. Holding	-
Public & others	34.8
<b>Total</b>	<b>100.0</b>

As on Dec 31, 2021

## Recommendation

**ACCUMULATE**

## Analyst

**KISHAN GUPTA, CFA, FRM**

Phone: + 91 (33) 4488 0043

E- mail: kishan.gupta@cdequi.com

## Highlights

- Helped by robust growth in phenolics and basic intermediates businesses, revenues from operations rose by 39.4% to Rs 1722.27 in Q3 compared to Rs 1234.69 crs in the same quarter a year ago. Backed by robust demand in India and in key export markets, DNL's phenolics business posted yet another record setting asset utilization rate (capacity utilization 117% for Q3), while the basic intermediates business profited from healthy product realizations as price hikes were undertaken to offset rising raw material prices. After a lull in demand, DNL's performance products business did show some traction last quarter for demand for DASDA improved resulting in higher realizations.
- Due to lag effect in passing on higher raw material prices and rising logistics costs, DNL's fine & specialty chemicals business did report barely indistinct drop in EBIT margins - 25.8% in Q3 vs 43.1% in Q3FY21 Vs 30.4% in Q2FY22. Margin suppression was also observed in DNL's basic intermediates (19.9% Vs 23.9%) and phenolics business (17.8% Vs 23.3%). Thanks to nearly 9% drop in revenues of phenolics business (compared to Q2), its EBIT dropped by over 16% to Rs 183.61 crs. Helped by higher margins of OBA, DNL's performance products business printed perceptible increase in EBIT margins (27.7% Vs 9%).
- Higher cost of utilities - fuel, furnace oil, coal - pressured overall operating profit (more so for energy intensive phenolics business) in Q3 as it drop by 9% from Q2 but rose by 5% on yoy basis. Yet OPM contracted alarmingly to 20.4% in Q3 from 27.1% in the same quarter a year ago and 23% in Q2. Higher other income hardly helped for post tax earnings rose by just 12% to Rs 242.46 crs in Q3 from Rs 216.56 crs reported in the same quarter a year ago.
- The stock currently trades at 29.6x FY22e EPS of Rs 77.27 and 25.2x FY23e EPS of Rs 90.76. Though earnings would jump by some 17.5% next fiscal on distinct expansion in margins, increased 'friction' from inflationary trends in energy prices could pose no small threat. DNL's phenolics business would be barely aloof from fast changing dynamics of global demand and supply impacting realizations. Capacity utilization of existing capacities will partly rest on streamlining of raw material availability. Weighing odds, we assign accumulate rating on the stock with revised target of Rs 2723 (previous target: Rs 2029) based on 30x FY23e earnings.

Consolidated (Rs crs)	FY19	FY20	FY21	FY22e	FY23e
Income from operations	2699.92	4229.71	4359.75	6639.84	7342.94
Other Income	15.12	35.20	21.52	55.80	47.97
EBITDA (other income included)	432.32	1064.10	1271.68	1631.73	1911.91
Profit after associate profit (adjusted for EO)	174.04	615.83	777.20	1053.88	1237.89
EPS (Rs)	12.76	45.15	56.98	77.27	90.76
EPS growth (%)	151.3	253.8	26.2	35.6	17.5

## Outlook & Recommendation


### Global Phenol Update

According to a report by Expert Market Research, the global phenol market is estimated to grow by a CAGR of 4.2% between 2022 and 2027 to reach a value of \$24.07 bn by 2027 from \$19.44 bn in 2021. Much of the past growth in phenol market has been driven by rising living standards and growing demand for alkyl phenols. The report outlines that Asia Pacific was the largest phenol market in 2021 with market share of 52.5% followed by Europe at 22.4% and US at 17% of the industry.

The demand for phenol has also been rising globally due to end use industries growth, increasing urbanization, changing lifestyles and the rise in disposable incomes globally. The end use sector is led by Bisphenol A, which accounted for 47% of the industry share. Phenol market is also getting a boost from strong growth in emerging markets and technological advancements in the techniques of its production.



Source: EMR



Source: EMR




The report further contends that global phenol market will also get a leg up from growing demand for phenol derivatives such as polycarbonate and epoxy resins in the automobile and construction sector. The construction industry, the report mentions, is expected to grow by 85% in 2030 to attain \$15.5 trillion, with China, US, and India accounting for 57% of the estimated growth. Further, India and China are emerging as two big automotive markets globally.

According to Fortune Business Insights, governments of several countries are giving greater impetus on increasing the manufacturing facilities of phenol as phenol is used in various industries such as chemicals, materials, automotive and others. Northern American region is expected to grow briskly thanks to increasing number of chemical companies in US and Canada. Capacity enhancement plans by leading phenol manufacturers will help them expand their business operations and widen their market presence.

### Financials & Valuation




Much of the Indian chemical industry is expected to be led by specialty chemicals as Indian chemical companies have plans to boost production to raise their export share. As a result, capacity expansions will be undertaken across the domestic industry with increased capital expenditure commitments. Indian manufacturing sector will get a boost from GOI's Aatmanirbhar Bharat and PLI schemes which will increase flow of orders.

After doubling of IPA capacity to 60000 mtpa, DNL plans to augment its pipeline of complex downstream products using fluorination with an investment of Rs 300 crs at a new site in Dahej. In addition to that, the company has also earmarked Rs 100 crs for various brown field expansions of existing products. Plans are also drawn for investing Rs 700 crs to add new solvents which are downstream of phenol and acetone. These solvents which are used in pharma and agrochemicals would also cater to coating segment.



Much of the revenue growth next fiscal would accrue from increased volumes as the company gears up to boost underutilized capacities in BI & FSC segments. Phenolics business growth would barely escape launch of new derivatives of phenol and acetone as phenol capacity utilization would hardly gain traction. Increased 'sales velocity' in performance products business not least due to increased of take would support higher margins. As raw material and utility prices ease next fiscal, EBIT margin of both phenol and FSC is estimated to rise.

The stock currently trades at 29.6x FY22e EPS of Rs 77.27 and 25.2x FY23e EPS of Rs 90.76. Addition of new chemistries by second half of next fiscal would scarcely prevent product portfolio expansion and widening of client base. Notwithstanding stress in margins from higher utility and raw material prices, margin would improve next fiscal from higher utilization and increased pricing power in FSC and performance products businesses (OPM: 25.4% in FY23 Vs 23.7% in FY22). Problem of shortage of raw material is expected to be sorted out in current fiscal. Balancing odds we assign accumulate rating on the stock with revised target of Rs 2723 (previous target: Rs 2029) based on 30x FY23e earnings. For more info refer to our May report.



## Cross Sectional Analysis

Company	Equity (Rs crs)	CMP (Rs crs)	Mcap (Rs crs)	Inc. from ops. (Rs crs)	Profit (Rs crs)	OPM (%)	NPM (%)	Int. cov.	ROE (%)	Mcap / IO	P/BV	P/E
Aarti Inds.	181	1022	37055	5822	732	20.9	12.6	9.0	17.0	6.4	6.4	50.6
Atul Ltd	30	9689	28666	4826	642	19.9	13.2	106.3	15.9	5.9	6.6	44.6
Deepak Nitrite	27	2290	31231	6393	1091	25.9	17.1	34.0	42.6	4.9	10.2	28.6
Sudarshan Chem	14	611	4227	2150	139	12.9	6.4	9.7	19.0	2.0	5.4	30.5





calculations on ttm basis

Companies not truly comparable due to product dissimilarities

Higher product prices did little to boost consolidated operating profit of Atul for it rose by 3.5% to Rs 251.47 crs compared to Rs 242.97 crs in the same quarter a year ago at a time when sales rose by a whopping 44.9% to Rs 1380.31 crs. Wherefore, OPMs slid to 18.2% from 25.5% and net profit tumbled by 17.6% to Rs 155.43 crs in Q3. Margin erosion was seen in both life science chemicals and performance and other chemicals businesses though the decline in margins was sharper in the latter, where EBIT margin dropped to 15.5% from 25.4% reported in the same quarter a year ago.

Buoyed by accrual of termination fees of Rs 631.25 crs arising out of termination of a long term supply contract by a customer, Aarti Industries published near doubling of revenues in Q3 (though adjusted revenues grew by 47%). Yet OPM shrunk to 19.2% from 24% in Q3 of last fiscal as the company experienced high inflation in raw materials. Robust revenue growth underscored cost pass through to customers though volumes of its nitric based products was impacted by shortage of nitric acid during the quarter. Robust capacity utilization barely withheld revenues for Aarti reported 85% utilization across most of its operational facilities.

Sudarshan's pigment industry has input cost escalation across multiple intermediates not least due to sharp increase in energy costs. Further cost escalations have come to fore from disruption in logistics. Although Sudarshan reported 18.8% growth in revenues in Q2 but much of it accrued because of intermediate price increase pass through; though capacity utilization at 80% also helped buoy revenues. Yet operating margins tumbled to 12.3% in Q3 from 15.7% in the same quarter a year ago as higher coal and logistics cost impede margins. Amplified by stress in margin, post tax earnings slid by 7.1% to Rs 36.38 crs in Q3.



## Financials

### Income Statement - Consolidated

Figures in Rs crs

	Q3FY22	Q3FY21	% chg.	9MFY22	9MFY21	% chg.
<b>Income from operations</b>	<b>1722.27</b>	<b>1234.69</b>	<b>39.5</b>	<b>4929.84</b>	<b>2896.52</b>	<b>70.2</b>
Other Income	25.75	4.88	427.7	39.07	15.58	150.8
<b>Total Income</b>	<b>1748.02</b>	<b>1239.57</b>	<b>41.0</b>	<b>4968.91</b>	<b>2912.10</b>	<b>70.6</b>
Total Expenditure	1370.42	899.65	52.3	3736.59	2104.15	77.6
<b>PBIDT (other income included)</b>	<b>377.60</b>	<b>339.92</b>	<b>11.1</b>	<b>1232.32</b>	<b>807.95</b>	<b>52.5</b>
Interest	6.80	15.70	-56.7	26.98	60.00	-55.0
Depreciation	45.47	33.92	34.1	133.08	96.17	38.4
<b>PBT</b>	<b>325.33</b>	<b>290.30</b>	<b>12.1</b>	<b>1072.26</b>	<b>651.78</b>	<b>64.5</b>
Tax	82.87	73.74	12.4	272.83	166.08	64.3
<b>PAT</b>	<b>242.46</b>	<b>216.56</b>	<b>12.0</b>	<b>799.43</b>	<b>485.70</b>	<b>64.6</b>
MI	-	-	-	-	-	-
<b>Net profit after MI</b>	<b>242.46</b>	<b>216.56</b>	<b>12.0</b>	<b>799.43</b>	<b>485.70</b>	<b>64.6</b>
Extraordinary Item	-	-	-	-	-	-
<b>Adjusted Net Profit</b>	<b>242.46</b>	<b>216.56</b>	<b>12.0</b>	<b>799.43</b>	<b>485.70</b>	<b>64.6</b>
EPS (F.V. 2)	17.78	15.88	12.0	58.61	35.61	64.6

### Segment Results

Figures in Rs crs

	Q3FY22	Q3FY21	% chg.	9MFY22	9MFY21	% chg.
<b>Segment Revenue</b>						
Basic Intermediates	345.81	196.24	76.2	862.19	514.96	67.4
Fine & Speciality Chemicals	206.66	210.93	-2.0	611.01	560.60	9.0
Performance Products	169.88	90.17	88.4	367.94	217.52	69.2
Phenolics	1033.11	746.92	38.3	3169.09	1622.97	95.3
<b>Total</b>	<b>1755.46</b>	<b>1244.26</b>	<b>41.1</b>	<b>5010.23</b>	<b>2916.05</b>	<b>71.8</b>
Inter segment revenue	33.19	9.57	246.8	80.39	19.53	311.6
<b>Income from operations</b>	<b>1722.27</b>	<b>1234.69</b>	<b>39.5</b>	<b>4929.84</b>	<b>2896.52</b>	<b>70.2</b>
<b>Segment EBIT</b>						
Basic Intermediates	68.74	46.88	46.6	216.29	124.16	74.2
Fine & Speciality Chemicals	53.23	90.99	-41.5	180.74	254.02	-28.8
Performance Products	47.01	8.16	476.1	58.69	19.58	199.7
Phenolics	183.61	173.83	5.6	691.26	365.79	89.0
<b>Total</b>	<b>352.59</b>	<b>319.86</b>	<b>10.2</b>	<b>1146.98</b>	<b>763.55</b>	<b>50.2</b>
Interest	6.80	15.70	-56.7	26.98	60.00	-55.0
Other Unallocable Exp. (net of income)	20.46	13.86	47.6	47.74	51.77	-7.8
<b>PBT</b>	<b>325.33</b>	<b>290.30</b>	<b>12.1</b>	<b>1072.26</b>	<b>651.78</b>	<b>64.5</b>

## Financials

### Income Statement - Consolidated

Figures in Rs crs

	FY19	FY20	FY21	FY22e	FY23e
<b>Income from operations</b>	<b>2699.92</b>	<b>4229.71</b>	<b>4359.75</b>	<b>6639.84</b>	<b>7342.94</b>
<i>Growth (%)</i>	65.5	56.9	3.1	52.3	10.6
Other Income	15.12	35.20	21.52	55.80	47.97
<b>Total Income</b>	<b>2715.04</b>	<b>4264.91</b>	<b>4381.27</b>	<b>6695.64</b>	<b>7390.91</b>
Total Expenditure	2282.72	3200.81	3109.59	5063.91	5479.00
<b>EBITDA (other income included)</b>	<b>432.32</b>	<b>1064.10</b>	<b>1271.68</b>	<b>1631.73</b>	<b>1911.91</b>
Interest	86.55	117.97	77.33	36.25	30.95
<b>EBDT</b>	<b>345.78</b>	<b>946.13</b>	<b>1194.35</b>	<b>1595.48</b>	<b>1880.96</b>
Depreciation	77.79	139.73	152.63	180.87	219.37
Tax	94.32	195.37	265.91	360.73	423.71
<b>Net profit after MI</b>	<b>173.67</b>	<b>611.03</b>	<b>775.81</b>	<b>1053.88</b>	<b>1237.89</b>
Extraordinary item	-0.38	-4.80	-1.39	-	-
<b>Adjusted Net Profit</b>	<b>174.04</b>	<b>615.83</b>	<b>777.20</b>	<b>1053.88</b>	<b>1237.89</b>
EPS (Rs.)	12.76	45.15	56.98	77.27	90.76

### Segment Results

Figures in Rs crs

	FY19	FY20	FY21	FY22e	FY23e
<b>Segment Revenue</b>					
Basic Intermediates	893.19	940.32	760.17	1212.19	1357.65
Fine & Speciality Chemicals	535.64	585.26	766.55	821.01	944.16
Performance Products	402.88	767.12	304.18	547.94	684.93
Phenolics/ others	908.01	2000.86	2560.51	4169.09	4481.20
<b>Total</b>	<b>2739.71</b>	<b>4293.56</b>	<b>4391.41</b>	<b>6750.23</b>	<b>7467.94</b>
Inter segment revenue	39.80	63.85	31.65	110.39	125.00
<b>Income from operations</b>	<b>2699.92</b>	<b>4229.71</b>	<b>4359.75</b>	<b>6639.84</b>	<b>7342.94</b>
<b>Segment EBIT</b>					
Basic Intermediates	145.35	209.35	194.87	293.29	325.84
Fine & Speciality Chemicals	126.55	175.24	333.73	239.54	283.25
Performance Products	83.23	418.62	22.63	103.69	136.99
Phenolics/ others	95.79	187.31	632.57	881.26	1030.68
<b>Sub Total</b>	<b>450.92</b>	<b>990.52</b>	<b>1183.80</b>	<b>1517.78</b>	<b>1776.75</b>
Interest	83.24	115.14	74.20	36.25	30.95
Other Unallocable Exp. (net of income)	99.70	68.98	67.88	66.92	84.20
<b>PBT</b>	<b>267.99</b>	<b>806.40</b>	<b>1041.72</b>	<b>1414.61</b>	<b>1661.59</b>

## Consolidated Balance Sheet

Figures in Rs crs

	FY19	FY20	FY21	FY22e	FY23e
<b>SOURCES OF FUNDS</b>					
Share Capital	27.28	27.28	27.28	27.28	27.28
Reserves	1044.31	1544.63	2319.37	3298.24	4447.47
<b>Total Shareholders Funds</b>	<b>1071.59</b>	<b>1571.91</b>	<b>2346.65</b>	<b>3325.52</b>	<b>4474.75</b>
Long term debt	869.86	792.89	534.80	275.00	215.00
<b>Total Liabilities</b>	<b>1941.46</b>	<b>2364.80</b>	<b>2881.45</b>	<b>3600.52</b>	<b>4689.75</b>
<b>APPLICATION OF FUNDS</b>					
Gross Block	1876.26	2128.53	2307.96	2907.96	3407.96
Less: Accumulated Depreciation	160.43	296.55	444.22	625.09	844.46
<b>Net Block</b>	<b>1715.83</b>	<b>1831.98</b>	<b>1863.74</b>	<b>2282.87</b>	<b>2563.50</b>
Capital Work in Progress	33.87	172.27	220.44	400.00	375.00
Investments	2.39	2.38	189.29	52.51	502.51
<b>Current Assets, Loans &amp; Advances</b>					
Inventory	410.73	394.50	382.69	535.77	616.13
Sundry Debtors	574.96	612.72	756.30	968.06	1084.23
Cash and Bank	25.77	31.40	33.43	65.39	107.89
Other Assets	150.26	117.68	92.97	93.21	101.21
<b>Total CA &amp; LA</b>	<b>1161.72</b>	<b>1156.30</b>	<b>1265.39</b>	<b>1662.43</b>	<b>1909.46</b>
Current liabilities	876.01	736.91	543.10	667.34	517.58
Provisions	7.62	12.04	10.38	10.30	10.50
<b>Total Current Liabilities</b>	<b>883.63</b>	<b>748.95</b>	<b>553.48</b>	<b>677.64</b>	<b>528.08</b>
Net Current Assets	278.09	407.35	711.91	984.80	1381.38
Net Deferred Tax (net of liability)	-77.46	-79.61	-107.81	-119.81	-129.81
Other Assets (Net of liabilities)	-11.27	30.43	3.88	0.15	-2.83
<b>Total Assets</b>	<b>1941.46</b>	<b>2364.80</b>	<b>2881.45</b>	<b>3600.52</b>	<b>4689.75</b>

**Key Financial Ratios**

	FY19	FY20	FY21	FY22e	FY23e
<b>Growth Ratios</b>					
Revenue (%)	65.5	56.9	3.1	52.3	10.6
EBIDTA (%)	123.3	147.3	19.0	28.1	17.2
Net Profit (%)	160.3	253.8	26.2	35.6	17.5
EPS (%)	151.3	253.8	26.2	35.6	17.5
<b>Margins</b>					
Operating Profit Margin (%)	15.5	24.5	28.7	23.7	25.4
Gross Profit Margin (%)	12.8	22.5	27.4	24.0	25.6
Net Profit Margin (%)	6.5	14.6	17.8	15.9	16.9
<b>Return</b>					
ROCE (%)	11.2	28.8	30.2	32.7	30.0
ROE (%)	17.9	47.2	40.4	38.3	32.5
<b>Valuations</b>					
Market Cap / Sales	1.4	1.2	5.2	4.7	4.3
EV/EBIDTA	11.3	5.9	18.0	19.2	16.4
P/E	21.5	8.5	29.1	29.6	25.2
P/BV	3.6	3.3	9.9	9.6	7.1
<b>Other Ratios</b>					
Interest Coverage	4.1	7.9	14.5	40.0	54.7
Debt-Equity Ratio	1.1	0.7	0.3	0.2	0.1
Current Ratio	1.3	1.5	2.3	2.2	3.8
<b>Turnover Ratios</b>					
Fixed Asset Turnover	2.3	2.4	2.4	3.2	3.0
Total Asset Turnover	1.6	2.0	1.7	2.1	1.8
Debtors Turnover	5.5	7.1	6.4	7.7	7.2
Inventory Turnover	6.2	7.9	8.0	11.0	9.5
Creditors Turnover	4.7	7.6	7.8	12.5	14.3
<b>WC Ratios</b>					
Debtor Days	66.8	51.2	57.3	47.4	51.0
Inventory Days	59.0	46.0	45.6	33.1	38.4
Creditor Days	77.1	47.8	47.0	29.3	25.6
Cash Conversion Cycle	48.7	49.4	55.9	51.2	63.8



**Cumulative Financial Data**

Figures in Rs crs	FY18-20	FY21-23e
Income from operations	8555	18343
Operating profit	1635	4692
EBIT	1427	4264
PBT	1175	4118
PAT	857	3069
Dividends	128	266
OPM (%)	19.1	25.6
NPM (%)	10.0	16.7
Interest coverage	5.7	29.5
ROE (%)	25.2	34.4
ROCE (%)	16.9	28.9
Debt-equity ratio*	0.7	0.1
Fixed asset turnover	2.4	2.8
Debtors turnover	5.9	7.2
Inventory turnover	8.2	9.0
Creditors turnover	8.0	12.0
Debtors days	62.3	50.7
Inventory days	44.4	40.5
Creditor days	45.8	30.4
Cash conversion cycle	60.9	60.8
Dividend payout ratio (%)	14.8	8.7

FY18-20 implies three years ending fiscal 20; \*as on terminal year; consolidated data

Record utilization of phenol capacity over the last few quarters (115% for FY21) would all but galvanize overall margins for OPM for three year period ended FY23 is estimated to jump to 25.6% from 19.1% in the preceding three year period (see table). Factors such as favorable pricing of phenol and acetone and higher operational efficiencies would aid this surge in margins. Buoyant pricing for most of the basic intermediates including fuel additives, would do little to stymie margins. Cumulative post tax earning is estimated to surge 3.6x to Rs 3069 crs during FY21-23 period from Rs 857 crs not least due to scarcely weak growth in FY21 and beyond.

Record profit would propel return on capital during FY21-23 period (ROE projected at 34.4% Vs 25.2%) despite distinct fall in financial leverage - interest coverage ratio estimated to jump to 29.5 from 5.7 in FY18-20 period; debt – equity ratio is projected to fall to 0.1 by FY23 from 0.7 in FY20. Inflationary trend in prices of chemicals in general - phenol, acetone, nitric acid etc - would do little to prevent surge in fixed asset turnover ratio - 2.8x projected fort FY21-23 period compared to 2.4 in FY18-20 period. Despite fall in debtors' days, overall cash conversion cycle would flat line (see table).

**Financial Summary – US dollar denominated**

million \$	FY19	FY20	FY21	FY22e	FY23e
Equity capital	3.9	3.6	3.7	3.6	3.6
Shareholders funds	150.2	208.5	309.0	430.0	580.8
Total debt	171.5	146.6	80.0	67.7	37.2
Net fixed assets (incl CWIP)	254.4	265.9	283.5	356.4	390.3
Investments	0.3	0.3	25.8	7.0	66.8
Net current assets	35.4	54.0	86.6	119.0	169.9
Total assets	277.4	313.7	381.8	466.5	609.4
Revenues	385.8	596.8	587.6	882.0	975.4
EBITDA	61.9	151.0	171.6	216.8	254.0
EBDT	49.6	134.4	161.2	211.9	249.9
PBT	38.4	114.7	140.4	187.9	220.7
Profit after associate profit	24.9	86.9	104.7	140.0	164.4
EPS(\$)	0.18	0.64	0.77	1.03	1.21
Book value (\$)	1.10	1.53	2.27	3.15	4.26

income statement figures translated at average rates; balance sheet and cash flow at year end rates; projections at current rates (Rs 75.28/\$). All dollar denominated figures adjusted for extraordinary items.

## Disclosure & Disclaimer

CD Equisearch Private Limited (hereinafter referred to as 'CD Equi') is a Member registered with National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange of India Limited (Formerly known as MCX Stock Exchange Limited). CD Equi is also registered as Depository Participant with CDSL and AMFI registered Mutual Fund Advisor. The associates of CD Equi are engaged in activities relating to NBFC-ND - Financing and Investment, Commodity Broking, Real Estate, etc.

CD Equi is registered under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration no INH300002274. Further, CD Equi hereby declares that –

- No disciplinary action has been taken against CD Equi by any of the regulatory authorities.
- CD Equi/its associates/research analysts do not have any financial interest/beneficial interest of more than one percent/material conflict of interest in the subject company(s) (*kindly disclose if otherwise*).
- CD Equi/its associates/research analysts have not received any compensation from the subject company(s) during the past twelve months.
- CD Equi/its research analysts has not served as an officer, director or employee of company covered by analysts and has not been engaged in market making activity of the company covered by analysts.

This document is solely for the personal information of the recipient and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved) and should consult their own advisors to determine the merits and risks of such an investment.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. CD Equi or any of its affiliates/group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. CD Equi has not independently verified all the information contained within this document. Accordingly, we cannot testify nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document.

While, CD Equi endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory compliance or other reasons that prevent us from doing so.

This document is being supplied to you solely for your information and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Neither, CD Equi nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

CD Equisearch Private Limited (CIN: U67120WB1995PTC071521)

Registered Office: 37, Shakespeare Sarani, 3rd Floor, Kolkata – 700 017; Phone: +91(33) 4488 0000; Fax: +91(33) 2289 2557 Corporate Office: 10, Vasawani Mansion, 5th Floor, DinshawWachha Road, Churchgate, Mumbai – 400 020. Phone: +91(22) 2283 0652/0653; Fax: +91(22) 2283, 2276 Website: www.cdequi.com; Email: research@cdequi.com

buy: >20%    accumulate: >10% to ≤20%    hold: ≥-10% to ≤10%    reduce: ≥-20% to <-10%    sell: <-20%

Exchange Rates Used- Indicative

Rs/\$	FY18	FY19	FY20	FY21
Average	64.45	69.89	70.88	74.20
Year end	65.04	69.17	75.39	73.50

All \$ values mentioned in the write-up translated at the average rate of the respective quarter/ year as applicable. Projections converted at current exchange rate. Cumulative dollar figure is the sum of respective yearly dollar value.